Document:

Document

BLADE AIR MOBILITY, INC. 2021 OMNIBUS INCENTIVE PLAN
RESTRICTED STOCK UNIT AWARD AGREEMENT 
BLADE AIR MOBILITY, INC., a Delaware corporation (the "Company"), hereby grants to the Participant named below an award (the "Award") of Restricted Stock Units ("RSUs"), payable in shares of the Company’s Common Stock (the “Shares”). The terms and conditions of the Award are set forth in this Award Agreement (the "Agreement") and the Blade Air Mobility, Inc. 2021 Omnibus Incentive Plan (the "Plan"), which is attached hereto as Exhibit A.
												
	
	Date of Grant	[DATE]	Participant's Name  [NAME]
	
	
	Number of RSUs	[X]		
	
	Vesting of RSUs	Subject to the (i) terms of the Plan, (ii) the forfeiture, cancellation, and rescission provisions of this Agreement and (iii) Participant complying with all Company policies, the Confidential Information, Invention Assignment and Arbitration Agreement by and between the Participant and the Company and all other agreements with the Company, the RSUs shall become vested as follows (each such date, a “Vesting Date”):
[X]
Except as otherwise provided in the Plan or this Agreement, any portion of this Award that is not vested on the date of Participant’s Termination shall be forfeited. Unless the Company or Committee provides otherwise in writing, the Participant shall not receive vesting credit for any period after the Participant provides notice of resignation.

	
	Payment Date	With respect to each Restricted Stock Unit that vests in accordance with this Agreement and the Plan, the Participant will be entitled to receive one Share in the calendar year in which the applicable Vesting Date occurs (each such date, a “Payment Date”), subject to the following: 
[X]

	

The provisions of the Plan are incorporated herein by reference. All capitalized terms that are not defined in this Agreement have the meanings set forth in the Plan. Except as otherwise expressly provided in this Agreement, in case of any conflict between this Agreement and the Plan, the terms of the Plan shall control.
Please (i) review the rest of this Agreement, the Plan document, and (ii) execute this Agreement.
By executing this Agreement, you agree to be bound by the terms and conditions of this Agreement (including the terms under "Forfeiture of Award" and “Cancellation and Rescission”). 

BLADE AIR MOBILITY, INC.

_____________________________
Robert S. Wiesenthal
Chief Executive Officer

PARTICIPANT

______________________________        __________________________
Name:                            Date

    

BLADE AIR MOBILITY, INC. 2021 OMNIBUS INCENTIVE PLAN
RESTRICTED STOCK UNIT AWARD AGREEMENT
The following additional terms and conditions supplement the terms of the Plan and govern this Award of Restricted Stock Units:

						
	Amount of RSU Payment
	The vested RSUs shall be settled in Shares at the time set forth in the cover page, with each vested RSU (before withholding) equal to one Share.

						
	Tax Withholding
	The Award is subject to withholding for taxes at the time and in the amount determined by the Company and/or Service Recipient. Regardless of the amount withheld or reported, the Participant acknowledges that the Participant is responsible for all taxes in respect of the Award (other than the employer’s share of employment taxes) and such taxes may exceed the amount withheld, if any. None of the Company, the Service Recipient, or any of their Affiliates or Subsidiaries: (a) make any representations or undertakings regarding taxes in respect of the Award, including the grant of the Award, the vesting or settlement of the Award, the subsequent sale of any Shares acquired pursuant to the Award and the receipt of any dividends or dividend equivalents; or (b) commit to structure the terms of the grant or any aspect of the Award to reduce or eliminate the Participant's liability for taxes.
Unless the Participant makes arrangements to pay withholding with cash, the number of Shares delivered upon settlement will be reduced to cover withholding. The reduction will be based on the fair market value of the Shares when withholding is due.
If the Participant relocates to another jurisdiction, the Participant is responsible for notifying the Company of such relocation and is responsible for compliance with all applicable tax requirements. If the Participant is subject to taxation in more than one jurisdiction, the Participant acknowledges that the Service Recipient may be required to withhold or account for Tax-Related Items in more than one jurisdiction. By accepting this Award, the Participant expressly consents to withholding in multiple jurisdictions, in the amounts and in the manner as the Company determines to be required by Applicable Law and the Plan.

    

						
	Post Change in Control Protection Period
	Notwithstanding any provision of this Agreement to the contrary, 100% of the unvested RSUs will vest if the Participant’s employment is terminated by the Service Recipient without Cause (other than due to death or Disability) or the Participant resigns for Good Reason, in each case during the period commencing three months prior to a Change in Control and ending 12 months following a Change in Control. To accomplish the foregoing, if the Participant experiences a termination by the Service Recipient without Cause (other than due to death or Disability) or the Participant resigns for Good Reason prior to a Change in Control, all then unvested RSUs shall remain outstanding following such termination or resignation and, (i) if a Change in Control occurs prior to the expiration of the three month period following such termination, such RSUs shall vest on the date of the Change in Control, or (ii) if no Change in Control occurs prior to the expiration of such three month period, the unvested RSUs will automatically expire at the end of such three month period. “Good Reason” shall mean the Participant’s resignation within 30 days following the expiration of any Service Recipient cure period (discussed below) following the occurrence of one or more of the following, without the Participant’s express written consent: (i) a material reduction of the Participant’s duties, or responsibilities, provided, that a change in job position (including a change in title) shall not be deemed a “material reduction” in and of itself unless the Participant’s new duties are materially reduced from the Participant’s prior duties; (ii) a material reduction in the Participant’s base salary (for clarity, a reduction by 10% or more will be considered a material reduction); provided, that an across the board base salary reduction to all senior executives of the Company will not be grounds for Good Reason; or (iii) a material change in the geographic location of the Participant’s primary work facility or location; provided, that a relocation of less than 30 miles from the Participant’s then present location will not be considered a material change in geographic location. The Participant will not resign for Good Reason without first providing the Service Recipient with written notice of the acts or omissions constituting the grounds for Good Reason within 90 days of the initial existence of the grounds for Good Reason and a cure period of not less than 30 days following the date of such notice. “Cause” shall mean the Participant’s (i) willful neglect in the performance of the Participant’s duties for the Service Recipient or willful or repeated failure or refusal to perform such duties; (ii) engagement in conduct in connection with the Participant’s employment or service with the Service Recipient, which results in, or could reasonably be expected to result in, material harm to the business or reputation of the Service Recipient or any other member of the Company Group; (iii) conviction of, or plea of guilty or no contest to (A) any felony or (B) any other crime that results in, or could reasonably be expected to result in, material harm to the business or reputation of the Service Recipient or any other member of the Company Group; (iv) material violation of the written policies of the Service Recipient, including, but not limited to, those relating to sexual harassment or the disclosure or misuse of confidential information, or those set forth in the manuals or statements of policy of the Service Recipient; (v) fraud or misappropriation, embezzlement, or misuse of funds or property belonging to the Service Recipient or any other member of the Company Group; or (vi) act of personal dishonesty that involves personal profit in connection with the Participant’s employment or service to the Service Recipient; provided, in any case, that the Participant’s resignation after an event that would be grounds for a Termination for Cause will be treated as a Termination for Cause hereund

    

						
	Dividend Equivalents
	The Participant shall be entitled to accrue dividend equivalents with respect to the Shares underlying the RSUs. For each Share, the Participant shall accrue a right to receive cash or share dividends for which the record date is after the Date of Grant and before the Award is settled. Such amounts shall be subject to the same forfeiture and vesting conditions as the underlying Shares, and shall be paid (if at all) at the same time as the RSUs are settled, applying the same vesting percentage as applies for the Share

						
	Cancellation and Rescission for Detrimental Activity
	Notwithstanding any other provision of the Plan or this Agreement, the Participant acknowledges and agrees that the Company may cancel, rescind, suspend, withhold, modify, amend or otherwise limit or restrict this Award (whether vested or not vested) at any time if the Participant is not in compliance with all applicable provisions of the Agreement and the Plan, or if the Participant engages in any Detrimental Activity (as the term is defined in the Plan). The Participant further acknowledges and agrees that, if the Participant engages in Detrimental Activity, as determined by the Committee in its sole discretion, whether during the Participant’s employment or service with the Service Recipient or following Termination, the Committee may, in its sole discretion and to the extent permitted by Applicable Law, provide for the cancellation of any or all of the Participant’s outstanding Awards and/or forfeiture by the Participant of any gains realized on the vesting or settlement of the Award, and repayment of any such gain promptly to the Company.
The Participant agrees that the cancellation, rescission and recoupment provisions of this Agreement are reasonable and agrees not to challenge the reasonableness of such provisions, even where forfeiture of this Agreement and/or recoupment of any gain hereunder is the penalty for violation; provided that the Participant may challenge the reasonableness of any forfeiture and/or recoupment that occurs after a Change in Control.

						
	No Employment Rights
	The grant of the Award shall not be interpreted to form an employment contract between the Participant and the Company and/or the Service Recipient.

						
	Discretionary Nature of Award
	The Participant acknowledges and agrees that the Plan is discretionary in nature and may be amended, canceled or terminated by the Company, in its sole discretion, at any time. The grant of this Award under the Plan is a one-time benefit and does not create any contractual or other right to receive a grant of RSUs or any other forms of Awards permitted under the Plan or other benefits in lieu thereof in the future. Future grants, if any (and the terms thereof), will be at the sole discretion of the Company. Any amendment, modification or termination of the Plan shall not constitute a change or impairment of the terms and conditions of the Participant's employment or service with the Service Recipie

    

						
	Extraordinary Benefit
	The Participant's participation in the Plan is voluntary. The value of this Award and any other Awards granted under the Plan is an extraordinary item of compensation outside the scope of the Participant's employment (and the Participant's employment contract, if any). Any grant under the Plan, including the grant of the Award, is not part of the Participant's normal or expected compensation for purposes of calculating any severance, resignation, redundancy, end of service payments, bonuses, long-service awards, holiday pay, pension, or retirement benefits or similar payment

						
	Value of Benefit
	The future value of the Award is unknown and cannot be predicted with certainty. The Company shall not be liable for any foreign exchange rate fluctuation, where applicable, between the Participant's local currency and the United States dollar or any other event that may affect the value of the Award or of any amounts due to the Participant pursuant to the settlement of the Award or the subsequent sale of any Shares acquired upon settlement.

						
	No Public Offering
	The grant of this Award is not intended to be a public offering of securities. No employee of the Company or its Subsidiaries or Affiliates is permitted to advise the Participant on whether the Participant should acquire Shares under the Plan and provide the Participant with any legal, tax or financial advice with respect to the grant of this Award. The acquisition of Shares involves certain risks, and the Participant should carefully consider all risk factors and tax considerations relevant to the acquisition and disposition of Shares under the Plan. Further, the Participant should carefully review all of the materials related to this Award and the Plan, and the Participant should consult with the Participant's personal legal, tax and financial advisers for professional advice in relation to the Participant's personal circumstance

						
	Insider Trading Laws
	By participating in the Plan, the Participant expressly agrees to comply with the Company’s insider trading policies and all Applicable Laws related to insider trading and fair dealing. Any restriction under Applicable Law is separate from and in addition to the restrictions imposed under Company policies. The Participant expressly acknowledges and agrees that it is the Participant's responsibility to comply with any applicable restrictions, and the Participant should consult the Participant’s personal adviser for additional information on any trading restrictions that may apply to the Participant.

    

						
	Recoupment
	Notwithstanding any other provision of this Agreement, the Participant acknowledges and agrees that this Award, any Shares acquired pursuant thereto and/or any amount received with respect to any sale of such Shares are subject to potential cancellation, recoupment, rescission, payback or other action in accordance with the terms of any recoupment policy that the Company, the Service Recipient, or any of their Subsidiaries or Affiliates may establish or adopt ("Recoupment Policy"), in each case as in effect and amended from time to time. The Participant agrees and consents to the Company's application, implementation and enforcement of (a) the Recoupment Policy, and (b) any provision of Applicable Law relating to cancellation, recoupment, rescission or payback of compensation and expressly agrees that the Company may take such actions as are necessary to effectuate the Recoupment Policy (as applicable to the Participant) or Applicable Law without further consent or action being required by the Participant. For purposes of the foregoing, the Participant expressly and explicitly authorizes the Company to issue instructions, on the Participant's behalf, to any brokerage firm and/or third party administrator engaged by the Company to hold the Participant's Shares and other amounts acquired under the Plan to re-convey, transfer or otherwise return such Shares and/or other amounts to the Company. To the extent that the terms of this Agreement and the Recoupment Policy conflict, the terms of the Recoupment Policy shall prevail. The provisions of this paragraph are in addition to, and not in lieu of, any provisions of this Agreement and/or the Plan relating to forfeiture and recoupment resulting from the Participant engaging in Detrimental Activit

						
	Electronic Delivery
	The Company may, in its sole discretion, decide to deliver any documents related to the Award or other awards granted to the Participant under the Plan by electronic means. The Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company

    

						
	Data Privacy
	The Company is located at New York, New York, United States of America and grants Awards under the Plan to employees of the Company and its Subsidiaries and Affiliates in its sole discretion. In conjunction with the Company’s grant of the Awards under the Plan and its ongoing administration of such Awards, the Company is providing the following information about its data collection, processing and transfer practices. In accepting the grant of this Award, the Participant expressly and explicitly consents to the personal data activities as described herein.

(a)Data Collection, Processing and Usage. The Company collects, processes and uses the Participant’s personal data, including the Participant’s name, home address, email address, telephone number, date of birth, social insurance number or other identification number, salary, citizenship, job title, any Shares or directorships held in the Company, and details of all Awards or any other equity compensation awards granted, canceled, exercised, vested, or outstanding in the Participant’s favor, which the Company receives from the Participant or the Service Recipient. In granting the Awards under the Plan, the Company will collect the Participant’s personal data for purposes of allocating Shares in settlement of the Awards and implementing, administering and managing the Plan. The Company’s legal basis for the collection, processing and usage of the Participant’s personal data is the Participant’s consent.

(b)Stock Plan Administration Service Provider. The Company may transfer the Participant’s personal data to an independent service provider in the United States of America to assist the Company with the implementation, administration and management of the Plan (the “Stock Plan Administrator”). The Stock Plan Administrator will open an account for the Participant to receive and trade Shares acquired under the Plan. The Participant will be asked to agree on separate terms and data processing practices with the Stock Plan Administrator, which is a condition to the Participant’s ability to participate in the Plan.

(c)Voluntariness and Consequences of Consent Denial or Withdrawal. The Participant’s participation in the Plan and the Participant’s grant of consent is purely voluntary. The Participant may deny or withdraw the Participant’s consent at any time. If the Participant does not consent, or if the Participant later withdraws the Participant’s consent, the Participant may be unable to participate in the Plan. This would not affect the Participant’s existing employment or salary; instead, the Participant merely may forfeit the opportunities associated with the Plan.

						
	Successors and Assigns
	The Company may assign any of its rights under this Agreement. This Agreement will be binding upon and inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this Agreement will be binding upon the Participant and the Participant's beneficiaries, executors and administrators.

    

						
	Additional Requirements
	The Company reserves the right to impose other requirements on the Award, any Shares acquired pursuant to the Award and the Participant's participation in the Plan to the extent the Company determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local law or to facilitate the operation and administration of the Award and the Plan. Such requirements may include (but are not limited to) requiring the Participant to sign any agreements or undertakings that may be necessary to accomplish the foregoing

						
	Severability
	The invalidity or unenforceability of any provision of the Plan or this Agreement will not affect the validity or enforceability of any other provision of the Plan or this Agreement, and each provision of the Plan and this Agreement will be severable and enforceable to the extent permitted by law.

						
	Interpretation and Construction
	This Agreement and the Plan shall be construed and interpreted by the Committee, in its sole discretion. Any interpretation or other determination by the Committee (including, but not limited to, correction of any defect or omission and reconciliation of any inconsistency in the Agreement or the Plan) shall be binding and conclusive.
All determinations regarding enforcement, waiver or modification of the cancellation and rescission and other provisions of this Agreement (including the provisions relating to Termination) shall be made in the Committee’s sole discretion. Determinations made under this Agreement and the Plan need not be uniform and may be made selectively among individuals, whether or not such individuals are similarly situated

						
	Section 409A of the Code
	Although the Company does not guarantee the particular tax treatment of the RSUs granted under this Agreement, the grant of RSUs under this Agreement is intended to comply with, or be exempt from, the applicable requirements of Section 409A of the Code and this Agreement shall be limited, construed and interpreted in accordance with such intent. In no event whatsoever shall the Company or any of its affiliates be liable for any additional tax, interest or penalties that may be imposed on the Participant by Section 409A of the Code or any damages for failing to comply with Section 409A of the Code. To the extent any payment made under this Agreement constitutes “non-qualified deferred compensation” pursuant to Section 409A of the Code, the provisions of Section 12(t) of the Plan shall apply.

						
	Entire Understanding
	This Agreement and the terms of the Plan constitute the entire understanding between the Participant and the Company and its Subsidiaries and Affiliates regarding this Award. Any prior agreements, commitments, or negotiations concerning this Award are superseded.

						
	Participant’s Acknowledgement and Agreement
	By accepting the grant of the Award, the Participant acknowledges that the Participant has read this Agreement and the Plan and the Participant specifically accepts and agrees to the provisions therein.Exhibit
10.1

 

WARRANT
EXERCISE AGREEMENT

 

This
WARRANT EXERCISE AGREEMENT (the “Agreement”), dated as of December 20, 2021, is made by and between Vinco Ventures,
Inc., a Nevada corporation, with headquarters located at 6 North Main Street, Fairport, NY 14450 (the “Company”),
and the investor listed on the signature page attached hereto (the “Holder”). Capitalized terms used herein and not
otherwise defined herein shall have the respective meanings set forth in the applicable Warrants (as defined below).

 

A.
Pursuant to that certain Securities Purchase Agreement (“July SPA”) dated as of July 22, 2021 by and between the Company
and the Holder, the Company sold to the Holder notes (the “July Notes”) and warrants, of which 30,258,848 remain outstanding
as of the date hereof (the “July Warrants”), representing the right to acquire shares of the Company’s common
stock, $0.001 par value per share (the “Common Stock”).

 

B.
The Company and the Holder desire: (i) for the Holder to exercise 13,634,685 July Warrants (the “Exercised Warrants”)
representing the right to acquire shares (the “Exercised Warrant Shares”) of Common Stock, (ii) for the Company to
issue additional warrants, in the form attached hereto as Exhibit A, to purchase shares of Common Stock at a per-share exercise
price equal to $3.2652, subject to adjustments as provided therein (the “December Warrants” and, together with the
July Warrants, the “Warrants”), all pursuant to the terms and conditions set forth herein, and (iii) to amend (A)
the Series A warrants (the “Series A September Warrant”) and the Series B warrants (the “Series B September
Warrant”) issued by the Company to the Holder pursuant to that certain Warrant Exercise Agreement dated as of September 1,
2021 by and among the Company and the Holder (“September WEA”) and (B) the warrants (the “November Warrant”)
issued by the Company to the Holder pursuant to that certain Warrant Exercise Agreement dated as of November 11, 2021 by and among the
Company and the Holder (“November WEA”).

 

C.
At the Closing (as defined in Section 2(b) hereof), the parties hereto shall execute and deliver a Registration Rights Agreement, in
the form attached hereto as Exhibit B (the “Registration Rights Agreement”), pursuant to which the Company
will agree to provide certain registration rights with respect to the Registrable Securities (as defined in the Registration Rights Agreement),
under the 1933 Act and the rules and regulations promulgated thereunder, and applicable state securities laws.

 

NOW
THEREFORE, in consideration of the foregoing mutual premises and the covenants and agreements hereinafter set forth, and for other
good and valuable consideration, the receipt, and legal adequacy of which is hereby acknowledged, the parties hereto, intending to be
legally bound, hereby agree as follows:

 

    	1

     

    

 

1.
EXERCISE OF EXERCISED WARRANTS AND ISSUANCE OF DECEMBER WARRANTS.

 

Subject
to the satisfaction (or waiver) of the conditions set forth in Sections 4 and 5 below, the Company and the Holder hereby agree that:
(i) the Holder shall pay to the Company an amount equal to the Exercise Price (as defined in each Exercised Warrant) in effect as of
the date of such exercise multiplied by the applicable Exercised Warrant Shares (such aggregate exercise price, the “Aggregate
Exercise Price”), (ii) the Company shall issue and deliver to the Holder the Exercised Warrant Shares as set forth in Section
1 of the Exercised Warrants and (iii) the Company shall issue and deliver to the Holder December Warrants to initially purchase an aggregate
number of shares equal to 225% of the number of Exercised Warrant Shares, which number of shares shall be subject to adjustments as set
forth therein.

 

2.
EXCHANGE; CLOSING.

 

(a)
Procedure. At or before the Closing, the Holder shall pay the Aggregate Exercise Price (less the Holder Counsel Expense withheld
pursuant to Section 7(l)) to the Company by wire transfer of immediately available funds in accordance with the Company’s written
wire instructions on Company letterhead signed by an authorized representative of the Company delivered to the Holder prior to the Closing,
and the Company shall credit to the balance account of the Holder with The Depository Trust Company through its Deposit / Withdrawal
at Custodian system (with such DWAC Instructions set forth in column (3) on Schedule I attached hereto), the Exercised Warrant Shares
pursuant to Section 1 of the Exercised Warrants.

 

(b)
Closing. The date and time of the closing (the “Closing”) of the transactions specified in Sections 1 and 2(a)
above (the “Closing Date”) shall be 9:00 a.m., New York City time, on December 20, 2021, subject to the notification
of satisfaction (or waiver) of the conditions to Closing set forth in Sections 4 and 5 hereof. The Closing shall occur at the offices
of Schulte Roth & Zabel LLP, 919 Third Avenue, New York, New York 10022 and may be undertaken remotely by electronic exchange of
documentation.

 

(c)
Buy-In. If the Company shall fail for any reason or for no reason to issue to the Holder on the Closing Date the Exercised Warrant
Shares by electronic delivery at the applicable balance account at DTC, and if on or after the Closing Date the Holder effects a Buy-In,
then the Company shall, within two (2) Trading Days after the Holder’s request and in the Holder’s discretion, either (i)
pay the Buy-In Price in cash, at which point the Company’s obligation to deliver such Exercised Warrant Shares (but not the Company’s
obligation to deliver Exercised Warrants pursuant to Section 1) shall terminate, or (ii) promptly honor its obligation to electronically
deliver to the Holder such unlegended Exercised Warrant Shares as provided above and pay cash to the Holder in an amount equal to the
excess (if any) of the Buy-In Price over the product of (A) such number of shares of Common Stock, times (B) any trading price of the
Common Stock selected by the Holder in writing as in effect at any time during the period beginning on the date hereof and ending on
the date the Company satisfies its obligations in full pursuant to this Section 2(c).

 

3.
REPRESENTATIONS, AGREEMENTS, WARRANTIES AND COVENANTS.

 

(a)
Holder Representations, Warranties and Covenants. The Holder hereby represents and warrants to the Company that:

 

(i)
Authorization; Enforcement; Validity. The Holder has the power and authority to execute and deliver this Agreement and perform
its obligations hereunder; and this Agreement and the transactions contemplated hereby have been duly authorized by the Holder. This
Agreement has been duly and validly authorized, executed and delivered on behalf of the Holder and shall constitute the legal, valid
and binding obligations of the Holder enforceable against the Holder in accordance with its terms, except as such enforceability may
be limited by general principles of equity or to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other
similar laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies.

 

    	2

     

    

 

(ii)
No Conflicts. The execution, delivery and performance by the Holder of this Agreement and the consummation by the Holder of the
transactions contemplated hereby will not (i) result in a violation of the organizational documents of the Holder or (ii) conflict with,
or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any
rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Holder is a party,
or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws)
applicable to the Holder, except in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or violations which
would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of the Holder to
perform its obligations hereunder.

 

(b)
Company Representations, Warranties and Covenants. The Company hereby represents, warrants, agrees and covenants, as applicable,
to and with the Holder that:

 

(i)
Solvency. Neither the Company nor any of its subsidiaries has taken any steps to seek protection pursuant to any bankruptcy law
nor does the Company have knowledge that its creditors or its subsidiaries’ creditors intend to initiate involuntary bankruptcy
proceedings or knowledge of any fact which would reasonably lead a creditor to do so. The Company and its subsidiaries, individually
and on a consolidated basis, are not as of the date hereof, and after giving effect to the transactions contemplated hereby will not
be, Insolvent. As used herein, “Insolvent” means, with respect to any Person, (i) the present fair saleable value
of such Person’s assets is less than the amount required to pay such Person’s total indebtedness, (ii) such Person is unable
to pay its debts and liabilities, subordinated, contingent or otherwise, as such debts and liabilities become absolute and matured, (iii)
such Person intends to incur or believes that it will incur debts that would be beyond its ability to pay as such debts mature or (iv)
such Person has unreasonably small capital with which to conduct the business in which it is engaged as such business is now conducted
and is proposed to be conducted.

 

(ii)
Organization and Qualification. Each of the Company and each of its subsidiaries are entities duly organized and validly existing
and in good standing under the laws of the jurisdiction in which they are formed, and have the requisite power and authorization to own
their properties and to carry on their business as now being conducted and as presently proposed to be conducted. Each of the Company
and each of its subsidiaries is duly qualified as a foreign entity to do business and is in good standing in every jurisdiction in which
its ownership of property or the nature of the business conducted by it makes such qualification necessary, except to the extent that
the failure to be so qualified or be in good standing would not reasonably be expected to have a Material Adverse Effect. As used in
this Agreement, “Material Adverse Effect” means any material adverse effect on the business, properties, assets, liabilities,
operations, results of operations, condition (financial or otherwise) or prospects of the Company and its subsidiaries, individually
or taken as a whole, or on the transactions contemplated hereby or by the agreements and instruments to be entered into in connection
herewith, or on the authority or ability of the Company to perform any of its obligations hereunder.

 

    	3

     

    

 

(iii)
Authorization; Enforcement; Validity. The Company has the requisite corporate power and authority to enter into and perform its
obligations under this Agreement, the Registration Rights Agreement and the December Warrants (collectively, the “Transaction
Documents”) and to issue the shares of Common Stock issuable upon the exercise of such December Warrants (the “December
Warrant Shares”) in accordance with the terms of the December Warrants. The execution and delivery of the Transaction Documents
by the Company and the consummation by the Company of the transactions contemplated thereby, including, without limitation, the issuance
of the December Warrant Shares, have been duly authorized by the Company’s Board of Directors and no further filing, consent or
authorization is required by the Company, its Board of Directors or its stockholders. Each of the Transaction Documents has been duly
executed and delivered by the Company, and constitute the legal, valid and binding obligations of the Company, enforceable against the
Company in accordance with their respective terms, except as such enforceability may be limited by general principles of equity or applicable
bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement
of applicable creditors’ rights and remedies.

 

(iv)
Issuance of Securities. The issuance of the Exercised Warrant Shares is duly authorized and, upon issuance in accordance with
the terms of the Exercised Warrants and hereof, the Exercised Warrant Shares shall be validly issued, fully paid and non-assessable and
free from all preemptive or similar rights, taxes, liens and charges and other encumbrances with respect to the issue thereof and the
Exercised Warrant Shares shall be fully paid and nonassessable with the holder thereof being entitled to all rights accorded to a holder
of Common Stock. As of the Closing, a registration statement or registration statements of the Company filed under the 1933 Act registering
the resale of the Exercised Warrant Shares by the Holder shall be effective and available for use by the Holder, and the Exercised Warrant
Shares shall not bear any restrictive legend and shall be freely tradable without any restrictions or limitations under applicable securities
laws, rules and regulations. The issuance of the December Warrants hereunder is duly authorized and upon issuance in accordance with
the terms of this Agreement and the December Warrants shall be validly issued, fully paid and non-assessable and free from all preemptive
or similar rights, mortgages, defects, claims, liens, pledges, charges, taxes, rights of first refusal, encumbrances, security interests
and other encumbrances (collectively “Liens”) with respect to the issuance thereof. As of the Closing, the Company
shall have reserved from its duly authorized capital stock not less than the maximum number of shares of Common Stock issuable upon the
exercise of the December Warrants issuable hereunder (without taking into account any limitations on the exercise of the December Warrants
and the Exercised Warrants set forth therein). Upon exercise in accordance with the December Warrants, the December Warrant Shares, when
issued, will be validly issued, fully paid and nonassessable and free from all preemptive or similar rights or Liens with respect to
the issue thereof, with the holders thereof being entitled to all rights accorded to a holder of Common Stock. Subject to the accuracy
of the representations and warranties of the Holder in this Agreement, the offer and issuance by the Company of the December Warrants
and the December Warrant Shares are exempt from registration under the 1933 Act.

 

    	4

     

    

 

(v)
No Conflicts. The execution, delivery and performance of this Agreement by the Company and the consummation by the Company of
the transactions contemplated hereby (including, without limitation, the issuance of the Exercised Warrant Shares and the issuance of
the December Warrant Shares) will not (i) result in a violation of the Company’s Certificate of Incorporation or Bylaws or other
organizational documents of the Company or any of its subsidiaries, any capital stock of the Company or any of its subsidiaries or the
articles of association or bylaws of the Company or any of its subsidiaries or (ii) conflict with, or constitute a default (or an event
which with notice or lapse of time or both would become a default) in any respect under, or give to others any rights of termination,
amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company or any of its subsidiaries is
a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including foreign, federal and state
securities laws and regulations and the rules and regulations of Principal Market and including all applicable foreign, federal laws,
rules and regulations) applicable to the Company or any of its subsidiaries or by which any property or asset of the Company or any of
its subsidiaries is bound or affected.

 

(vi)
Consents. The Company is not required to obtain any consent from, authorization or order of, or make any filing or registration
with any court, governmental agency or any regulatory or self-regulatory agency or any other Person in order for it to execute, deliver
or perform any of its obligations under or contemplated by this Agreement in accordance with the terms hereof. All consents, authorizations,
orders, filings and registrations which the Company is required to obtain pursuant to the preceding sentence have been obtained or effected
on or prior to the Closing Date, and the Company is unaware of any facts or circumstances which might prevent the Company from obtaining
or effecting any of the registration, application or filings contemplated by this Agreement. The Company is not in violation of the requirements
of the Principal Market and has no knowledge of any facts or circumstances which could reasonably lead to delisting or suspension of
the Common Stock in the foreseeable future. The issuance by the Company of the Exercised Warrant Shares shall not have the effect of
delisting or suspending the Common Stock from the Principal Market.

 

(vii)
Absence of Litigation. There is no action, suit, proceeding, inquiry or investigation before or by the Principal Market, any court,
public board, government agency, self-regulatory organization or body pending or, to the knowledge of the Company, threatened against
or affecting the Company or any of its subsidiaries, the Common Stock or any of the Company’s subsidiaries or any of the Company’s
or its subsidiaries’ officers or directors, whether of a civil or criminal nature or otherwise, in their capacities as such.

 

(viii)
SEC Filings. As of their respective filing dates, the Company’s filings with the SEC under the 1934 Act during the two (2)
years prior to the date hereof (the “SEC Documents”), complied in all material respects with the requirements of the
1934 Act and the rules and regulations of the SEC promulgated thereunder applicable to the SEC Documents, and none of the SEC Documents,
at the time they were filed with the SEC, contained any untrue statement of a material fact or omitted to state a material fact required
to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made,
not misleading. The Company represents that, as of the date hereof, no material event or circumstance has occurred which would be required
to be publicly disclosed or announced on a Current Report on Form 8-K, either as of the date hereof or solely with the passage of time
by the Company but which has not been so publicly announced or disclosed.

 

    	5

     

    

 

(ix)
Disclosure of Transactions and Other Material Information. The Company shall file a current report on Form 8-K (the “8-K
Filing”) on or before 8:30 a.m., New York City time, on the date this Agreement has been duly executed and delivered, in the
form required by the 1934 Act, relating to the transactions contemplated by this Agreement and attaching a form of this Agreement, a
form of the December Warrant and a form of the Registration Rights Agreement (including, without limitation, all schedules and exhibits
to such agreement, if any) as an exhibit to such filing. From and after the filing of the 8-K Filing with the SEC, the Holder shall not
be in possession of any material, nonpublic information received from the Company, any of its subsidiaries or any of their respective
officers, directors, Affiliates, employees or agents, that is not disclosed in the 8-K Filing. In addition, effective upon the filing
of the 8-K Filing, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether
written or oral, between the Company, any of its subsidiaries or any of their respective officers, directors, Affiliates, employees or
agents, on the one hand, and the Holder or any of its Affiliates, on the other hand, shall terminate and be of no further force or effect.
The Company shall not, and shall cause each of its subsidiaries and its and each of their respective officers, directors, Affiliates,
employees and agents, not to, provide the Holder with any material, nonpublic information regarding the Company or any of its subsidiaries
from and after the date hereof without the express prior written consent of the Holder. To the extent that the Company, any of its subsidiaries
or any of their respective officers, directors, Affiliates employees or agents delivers any material, non-public information to the Holder
without the Holder’s express prior written consent, the Company hereby covenants and agrees that the Holder’s shall not have
any duty of confidentiality to the Company, any of its subsidiaries or any of their respective officers, directors, Affiliates, employees
or agents with respect to, or a duty to the Company, any of its subsidiaries or any of their respective officers, directors, Affiliates,
employees or agents not to trade on the basis of, such material, non-public information. The Company understands and confirms that the
Holder will rely on the foregoing representations in effecting transactions in securities of the Company. The definition of “Disclosure
Restitution Amount” in the July SPA is hereby amended, solely with respect to the Holder, to include any December Warrant Shares.

 

(x)
Listing. The Company shall promptly secure the listing of all of (i) the December Warrant Shares and the Exercised Warrant Shares
and (ii) any capital stock of the Company issued or issuable with respect to the December Warrant Shares and the Exercised Warrant Shares,
as applicable, as a result of any stock split, stock dividend, recapitalization, exchange or similar event or otherwise (the “Listed
Securities”) upon each national securities exchange and automated quotation system, if any, upon which the Common Stock is
then listed (subject to official notice of issuance) and shall maintain such listing of all Listed Securities. The Company shall pay
all fees and expenses in connection with satisfying its obligations under this Section 3(b)(x).

 

(xi)
Reporting Status. Until the date on which the Holder has sold all the Exercised Warrant Shares and December Warrant Shares, the
Company shall timely file all reports required to be filed with the SEC pursuant to the 1934 Act, and the Company shall not terminate
its status as an issuer required to file reports under the 1934 Act even if the 1934 Act or the rules and regulations thereunder would
no longer require or otherwise permit such termination.

 

    	6

     

    

 

(xii)
No Integration Actions. None of the Company, any of its Affiliates or any Person acting on behalf of the Company or such Affiliate
will sell, offer for sale or solicit offers to buy in respect of any security (as defined in the 1933 Act) that would be integrated with
the issuance of the December Warrants or the December Warrant Shares in a manner that would require the registration under the 1933 Act
of the issuance to the Holder or require shareholder approval under the rules and regulations of the Principal Market, and the Company
will take all action that is appropriate or necessary to assure that its offerings of other securities will not be integrated for purposes
of the 1933 Act or the rules and regulations of the Principal Market with the issuance of the December Warrants and the December Warrant
Shares contemplated hereby.

 

(xiii)
Outstanding Shares. As of the date hereof, there are 136,483,339 shares of Common Stock issued and outstanding.

 

(xiv)
Investment Company Status. The Company is not, and upon consummation of the transactions contemplated hereunder will not be, an
“investment company,” an affiliate of an “investment company, “ a company controlled by an “investment
company” or an “affiliated person” of, or “promoter” or “principal underwriter” for, an “investment
company” as such terms are defined in the Investment Company Act of 1940, as amended.

 

(xv)
Illegal or Unauthorized Payments; Political Contributions. Neither the Company nor any of its Subsidiaries nor, to the best of
the Company’s knowledge (after reasonable inquiry of its officers and directors), any of the officers, directors, employees, agents
or other representatives of the Company or any of its Subsidiaries or any other business entity or enterprise with which the Company
or any Subsidiary is or has been affiliated or associated, has, directly or indirectly, made or authorized any payment, contribution
or gift of money, property, or services, whether or not in contravention of applicable law, (i) as a kickback or bribe to any Person
or (ii) to any political organization, or the holder of or any aspirant to any elective or appointive public office except for personal
political contributions not involving the direct or indirect use of funds of the Company or any of its Subsidiaries.

 

(xvi)
Money Laundering. The Company and its Subsidiaries are in compliance with, and have not previously violated, the USA Patriot Act
of 2001 and all other applicable U.S. and non-U.S. anti-money laundering laws and regulations, including, without limitation, the laws,
regulations and Executive Orders and sanctions programs administered by the U.S. Office of Foreign Assets Control, including, but not
limited, to (x) Executive Order 13224 of September 23, 2001 entitled, “Blocking Property and Prohibiting Transactions With Persons
Who Commit, Threaten to Commit, or Support Terrorism” (66 Fed. Reg. 49079 (2001)); and (y) any regulations contained in 31 CFR,
Subtitle B, Chapter V.

 

    	7

     

    

 

(xvii)
Acknowledgement Regarding Holder’s Trading Activity. It is understood and acknowledged by the Company that (i) following
the public disclosure of the transactions contemplated by the Transaction Documents, in accordance with the terms thereof, the Holder
has not been asked by the Company or any of its Subsidiaries to agree, nor has the Holder agreed with the Company or any of its Subsidiaries,
to desist from effecting any transactions in or with respect to (including, without limitation, purchasing or selling, long and/or short)
any securities of the Company, or “derivative” securities based on securities issued by the Company or to hold any securities
for any specified term; (ii) the Holder, and counterparties in “derivative” transactions to which the Holder is a party,
directly or indirectly, presently may have a “short” position in the Common Stock which was established prior to such Holder’s
knowledge of the transactions contemplated by the Transaction Documents; (iii) the Holder shall not be deemed to have any affiliation
with or control over any arm’s-length counterparty in any “derivative” transaction; and (iv) the Holder may rely on
the Company’s obligation to timely deliver shares of Common Stock upon conversion, exercise or exchange, as applicable, of the
Exercised Warrants and the December Warrants as and when required pursuant to the terms thereof for purposes of effecting trading in
the Common Stock of the Company. The Company further understands and acknowledges that following the public disclosure of the transactions
contemplated by the Transaction Documents pursuant to the 8-K Filing the Holder may engage in hedging and/or trading activities (including,
without limitation, the location and/or reservation of borrowable shares of Common Stock) at various times during the period that the
Exercised Warrants, the December Warrants or the shares of Common Stock issuable upon exercise thereof are outstanding, including, without
limitation, during the periods that the value and/or number of the such shares of Common Stock deliverable thereunder are being determined
and such hedging and/or trading activities (including, without limitation, the location and/or reservation of borrowable shares of Common
Stock), if any, can reduce the value of the existing stockholders’ equity interest in the Company both at and after the time the
hedging and/or trading activities are being conducted. The Company further understands and acknowledges that, prior to December 19, 2021,
the Company had provided no material nonpublic information to the Holder, and the Holder may have engaged in such hedging and/or trading
activities prior to such time. The Company acknowledges that such aforementioned hedging and/or trading activities do not constitute
a breach of this Agreement or any other Transaction Document or any of the documents executed in connection herewith or therewith.

 

(xviii)
Additional Registration Statements. Until the thirtieth (30th) calendar day after the Closing Date and at any time thereafter
while any Registration Statement (as defined in each of the Registration Rights Agreements between the Company and the Holder dated as
of February 23, 2021, May 24, 2021, June 4, 2021, July 22, 2021, August 18, 2021, September 1, 2021, November 11, 2021 and December 20,
2021) is not effective or the prospectus contained therein is not available for use or any Current Public Information Failure (as defined
in each of the Registration Rights Agreements between the Company and the Holder dated as of February 23, 2021, May 24, 2021, June 4,
2021, July 22, 2021, August 18, 2021, September 1, 2021, November 11, 2021 and December 20, 2021) exists, notwithstanding anything herein
to the contrary, the Company shall not file a registration statement or an offering statement under the 1933 Act relating to securities,
other than for securities to be sold by the Holder and its Affiliates (other than a registration statement on Form S-8 or such supplements
or amendments to registration statements that are outstanding and have been declared effective by the SEC as of the date hereof (solely
to the extent necessary to keep such registration statements effective and available and not with respect to any Subsequent Placement
(as defined in the July SPA)).

 

    	8

     

    

 

(xix)
Additional Issuance of Securities. The Company agrees that for the period commencing on the date hereof and ending on the 30th
calendar day after the Closing Date (the “Restricted Period”), neither the Company nor any of its Subsidiaries shall
directly or indirectly issue, offer, sell, grant any option or right to purchase, or otherwise dispose of (or announce any issuance,
offer, sale, grant of any option or right to purchase or other disposition of) any equity security or any equity-linked or related security
(including, without limitation, any “equity security” (as that term is defined under Rule 405 promulgated under the 1933
Act) or any Convertible Securities (as defined in the July SPA). Notwithstanding the foregoing, this Section 4(b)(xix) shall not apply
in respect of the issuance of (i) shares of Common Stock or standard options to purchase Common Stock to directors, officers or employees
of the Company in their capacity as such pursuant to an Approved Stock Plan (as defined in the July SPA), provided that (1) all
such issuances (taking into account the shares of Common Stock issuable upon exercise of such options) after the date hereof pursuant
to this clause (i) do not, in the aggregate, exceed more than 10% of the Common Stock issued and outstanding immediately prior to the
date hereof and (2) the exercise price of any such options is not lowered, none of such options are amended to increase the number of
shares issuable thereunder and none of the terms or conditions of any such options are otherwise materially changed in any manner that
adversely affects the Holder; (ii) shares of Common Stock issued upon the conversion or exercise of Convertible Securities (other than
standard options to purchase Common Stock issued pursuant to an Approved Stock Plan that are covered by clause (i) above) issued prior
to the date hereof, provided that the conversion, exercise or other method of issuance (as the case may be) of any such Convertible Security
is made solely pursuant to the conversion, exercise or other method of issuance (as the case may be) provisions of such Convertible Security
that were in effect on the date immediately prior to the date of this Agreement, the conversion, exercise or issuance price of any such
Convertible Securities (other than standard options to purchase Common Stock issued pursuant to an Approved Stock Plan that are covered
by clause (i) above) is not lowered, none of such Convertible Securities (other than standard options to purchase Common Stock issued
pursuant to an Approved Stock Plan that are covered by clause (i) above) are amended to increase the number of shares issuable thereunder
and none of the terms or conditions of any such Convertible Securities (other than standard options to purchase Common Stock issued pursuant
to an Approved Stock Plan that are covered by clause (i) above) are otherwise materially changed in any manner that adversely affects
the Holder; (iii) the Conversion Shares (as defined in the July SPA), and (iv) the Warrant Shares (as defined in the July SPA), the August
Warrant Shares (as defined in that certain Warrant Exercise Agreement, dated as of August 18, 2021), the September Warrant Shares (as
defined in the September WEA), the November Warrant Shares (as defined in the November WEA) and the December Warrant Shares (each of
the foregoing in clauses (i) through (iv), collectively the “Excluded Securities”). “Approved Stock Plan”
means any employee benefit plan which has been approved by the board of directors of the Company prior to or subsequent to the date hereof
pursuant to which shares of Common Stock and standard options to purchase Common Stock may be issued to any employee, officer or director
for services provided to the Company in their capacity as such.

 

    	9

     

    

 

(xx)
Removal of Legends. Certificates evidencing any December Warrant Shares shall not be required to contain the legend set forth
in Section 6(c) of the July SPA or any other legend (i) while a registration statement (including a Registration Statement) covering
the resale of such December Warrant Shares is effective under the 1933 Act, (ii) following any sale of such December Warrant Shares pursuant
to Rule 144 (assuming the transferor is not an affiliate of the Company), (iii) if such December Warrant Shares are eligible to be sold,
assigned or transferred under Rule 144 (provided that the Holder provides the Company with reasonable assurances that such December
Warrant Shares are eligible for sale, assignment or transfer under Rule 144 which shall not include an opinion of the Holder’s
counsel), (iv) in connection with a sale, assignment or other transfer (other than under Rule 144), provided that the Holder provides
the Company with an opinion of counsel to the Holder, in a generally acceptable form, to the effect that such sale, assignment or transfer
of the December Warrant Shares may be made without registration under the applicable requirements of the 1933 Act or (v) if such legend
is not required under applicable requirements of the 1933 Act (including, without limitation, controlling judicial interpretations and
pronouncements issued by the SEC). If a legend is not required pursuant to the foregoing, the Company shall no later than two (2) Trading
Days (or such earlier date as required pursuant to the 1934 Act or other applicable law, rule or regulation for the settlement of a trade
initiated on the date the Holder delivers such legended certificate representing such December Warrant Shares to the Company) following
the delivery by the Holder to the Company or the transfer agent (with notice to the Company) of a legended certificate representing such
December Warrant Shares (endorsed or with stock powers attached, signatures guaranteed, and otherwise in form necessary to affect the
reissuance and/or transfer, if applicable), together with any other deliveries from the Holder as may be required above in this Section
3(b)(xx), as directed by the Holder, either: (A) provided that the Company’s transfer agent is participating in the DTC Fast Automated
Securities Transfer Program, credit the aggregate number of shares of Common Stock to which the Holder shall be entitled to the Holder’s
or its designee’s balance account with DTC through its Deposit/Withdrawal at Custodian system or (B) if the Company’s transfer
agent is not participating in the DTC Fast Automated Securities Transfer Program, issue and deliver (via reputable overnight courier)
to the Holder, a certificate representing such December Warrant Shares that is free from all restrictive and other legends, registered
in the name of the Holder or its designee. Section 6(e) of the July SPA is hereby amended, solely with respect to the Holder, to include
any December Warrant Shares.

 

(xxi)
Registration Statement. As of the Closing Date, the Company’s Registration Statement on Form S-1 (Registration No. 333-260080)
(x) shall be effective and available for use by the Holder for the sale of any shares issuable upon the exercise of any Exercised Warrants,
(y) will not contain, as of the Closing Date, any untrue statement of a material fact or omit to state a material fact required to be
stated therein or necessary to make the statements therein not misleading and (z) will comply in all material respects with the 1933
Act and the applicable rules and regulations of the SEC thereunder.

 

(xxii)
Placement Agent’s and Advisor’s Fees. The Company has not paid or incurred, and will not pay or incur, any brokerage
or finder’s fees or commissions other financial advisory fees with respect to the transactions contemplated by the Transaction
Documents payable in cash. The Company agrees that it will not pay or incur any brokerage or finder’s fees or commissions other
financial advisory fees with respect to any other financing transactions or any amendments or waivers to any existing financing transactions
from the date hereof until the later of (x) the first date on which the resale by the Holder of all the Registrable Securities (as defined
in each of the Registration Rights Agreements between the Company and the Holder dated as of February 23, 2021, May 24, 2021, June 4,
2021, July 22, 2021, August 18, 2021, September 1, 2021, November 11, 2021 and December 20, 2021) is declared effective by the SEC (and
each prospectus contained therein is available for use on such date) and (y) the date the Stockholder Approval (as defined herein) has
been obtained.

 

    	10

     

    

 

4.
CONDITIONS TO ComPANY’S OBLIGATIONs hereunder.

 

The
obligations of the Company to the Holder hereunder are subject to the satisfaction of each of the following conditions, provided that
these conditions are for the Company’s sole benefit and may be waived by the Company at any time in its sole discretion by providing
the Holder with prior written notice thereof:

 

(a)
The Holder shall have duly executed this Agreement and delivered the same to the Company; and

 

(b)
The representations and warranties of the Holder shall be true and correct as of the date when made and as of the Closing Date as though
made at that time (except for representations and warranties that speak as of a specific date which shall be true and correct as of such
specified date), and the Holder shall have performed, satisfied and complied with the covenants, agreements and conditions required by
this Agreement to be performed, satisfied or complied with by the Holder at or prior to the Closing Date.

 

5.
CONDITIONS TO HOLDER’S OBLIGATIONs HEREUNDER.

 

The
obligations of the Holder hereunder are subject to the satisfaction of each of the following conditions, provided that these conditions
are for the Holder’s sole benefit and may be waived by the Holder in respect of itself at any time in its sole discretion by providing
the Company with prior written notice thereof:

 

(a)
The Company shall have duly executed this Agreement, the Registration Rights Agreement and the December Warrants and delivered the same
to the Holder;

 

(b)
The Company’s Registration Statement on Form S-1 (Registration No. 333-260080) shall be effective and available for use by the
Holder for the sale of any shares issuable upon the exercise of any Exercised Warrants;

 

(c)
The Company shall have obtained the listing of all of the December Warrant Shares on each Eligible Market on which the Common Stock is
then listed for trading;

 

(d)
The representations and warranties of the Company under this Agreement shall be true and correct in all respects as of the date when
made and as of the Closing Date as though made at that time (except for representations and warranties that speak as of a specific date
which shall be true and correct as of such specified date) and the Company shall have performed, satisfied and complied in all respects
with the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at
or prior to the Closing Date;

 

(e)
The Common Stock (i) shall be designated for quotation or listed on the Principal Market and (ii) shall not have been suspended, as of
the Closing Date, by the SEC or the Principal Market from trading on the Principal Market nor shall suspension by the SEC or the Principal
Market have been threatened, as of the Closing Date, either (A) in writing by the SEC or the Principal Market or (B) by falling below
the minimum listing maintenance requirements of the Principal Market;

 

    	11

     

    

 

(f)
Counsel for the Company shall have delivered a legal opinion to the Company’s transfer agent instructing the transfer agent to
deliver the Exercised Warrant Shares to the Holder’s balance account with The Depository Trust Company through its Deposit / Withdrawal
at Custodian system in accordance with the provisions of Section 2(a) hereof, and the Company’s transfer agent shall have delivered
the Exercised Warrant Shares to such balance account;

 

(g)
The Company shall have obtained all governmental, regulatory or third party consents and approvals, if any, necessary for the transactions
contemplated hereby; and

 

(h)
Since the date hereof, no event that could be reasonably expected to cause a Material Adverse Effect shall have occurred.

 

6.
TERMINATION.

 

In
the event that the Closing shall not have occurred by on or before five (5) Business Days from the date hereof, other than due to the
Holder’s failure to satisfy the conditions set forth in Section 4 hereof, the Holder shall have the option to terminate this Agreement
at the close of business on such date without liability of any party to any other party. Upon such termination, the terms hereof shall
be null and void.

 

7.
MISCELLANEOUS.

 

(a)
Governing Law; Jurisdiction; Jury Trial. All questions concerning the construction, validity, enforcement and interpretation of
this Agreement shall be governed by the internal laws of the State of New York, without giving effect to any choice of law or conflict
of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of
any jurisdictions other than the State of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state
and federal courts sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection
herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in
any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action
or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby
irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing
a copy thereof to such party at the address for such notices to it under this Agreement and agrees that such service shall constitute
good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to
serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST,
A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION
CONTEMPLATED HEREBY.

 

(b)
Counterparts. This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the
same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided
that a facsimile signature shall be considered due execution and shall be binding upon the signatory thereto with the same force and
effect as if the signature were an original, not a facsimile signature.

 

    	12

     

    

 

(c)
Headings. The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation
of, this Agreement.

 

(d)
Severability. If any provision of this Agreement is prohibited by law or otherwise determined to be invalid or unenforceable by
a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended
to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall
not affect the validity of the remaining provisions of this Agreement so long as this Agreement as so modified continues to express,
without material change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity
or unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations
of the parties or the practical realization of the benefits that would otherwise be conferred upon the parties. The parties will endeavor
in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of
which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).

 

(e)
Entire Agreement; Amendments. This Agreement shall supersede all other prior oral or written agreements among the Holder, the
Company, their Affiliates and persons acting on their behalf with respect to the matters discussed herein and therein, and this Agreement,
and the instruments referenced herein contain the entire understanding of the parties with respect to the matters covered herein and
therein. No provision of this Agreement may be amended other than by an instrument in writing signed by the Company and the Holder, and
any amendment to this Agreement made in conformity with the provisions of this Section 7(e) shall be binding on the Holder and the Company.
No provision hereof may be waived other than by an instrument in writing signed by the party against whom enforcement is sought.

 

(f)
Notices. Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement
must be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when sent
by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending party)
or electronic mail (provided that such sent email is kept on file (whether electronically or otherwise) by the sending party and the
sending party does not receive an automatically generated message from the recipient’s email server that such e-mail could not
be delivered to such recipient); or (iii) three (3) Business Days after deposit with an overnight courier service with next day delivery
specified, in each case, properly addressed to the party to receive the same. The addresses, facsimile numbers and e-mail addresses for
such communications shall be:

 

If
to the Company:

 

Vinco
Ventures, Inc.

6 North Main Street

Fairport, NY 14450

Telephone: (866) 900-0992

Facsimile: (908) 235-4373

Attention: Chief Executive Officer

E-Mail: Lking@Vincoventures.com

 

    	13

     

    

 

With
a copy (for informational purposes only) to:

 

Lucosky
Brookman LLP

101 Wood Avenue South, 5th Floor

Woodbridge, New Jersey 08830

Telephone: (732) 395-4400

Facsimile: (732) 395-4401

Attention: Joseph Lucosky, Esq.; Adele Hogan, Esq.

E-Mail: jlucosky@lucbro.com; ahogan@lucbro.com

 

If
to the Transfer Agent:

 

Nevada
Agency and Transfer Company

50 W. Liberty Street, Suite 880

Reno, Nevada 89501

Telephone: (775) 322-0626

Facsimile: (775) 322-5623

Attention: Tiffany Baxter

E-Mail: stocktransfer@natco.com

 

If
to a Buyer, to its address, e-mail address and facsimile number set forth on the Schedule of Buyers, with copies to such Buyer’s
representatives as set forth on the Schedule of Buyers,

 

with
a copy (for informational purposes only) to:

 

Schulte
Roth & Zabel LLP

919 Third Avenue

New York, New York 10022

Telephone: (212) 756-2000

Facsimile: (212) 593-5955

Attention: Eleazer N. Klein, Esq.

E-mail: eleazer.klein@srz.com

 

or
to such other address, e-mail address and/or facsimile number and/or to the attention of such other Person as the recipient party has
specified by written notice given to each other party five (5) days prior to the effectiveness of such change, provided that Schulte
Roth & Zabel LLP shall only be provided copies of notices sent to the lead Buyer. Written confirmation of receipt (A) given by the
recipient of such notice, consent, waiver or other communication, (B) mechanically or electronically generated by the sender’s
facsimile machine or e-mail containing the time, date, recipient facsimile number and, with respect to each facsimile transmission, an
image of the first page of such transmission or (C) provided by an overnight courier service shall be rebuttable evidence of personal
service, receipt by facsimile or receipt from an overnight courier service in accordance with clause (i), (ii) or (iii) above, respectively.

 

    	14

     

    

 

(g)
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors
and assigns, including any purchasers of the December Warrants.

 

(h)
No Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted
successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

 

(i)
Survival. The representations, warranties and covenants of the Company and the Holder contained herein shall survive the Closing
and delivery of the December Warrant Shares.

 

(j)
Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and
shall execute and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably request
in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated
hereby.

 

(k)
No Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party.

 

(l)
Fees and Expenses. Unless the Holder elects to withhold the Holder Counsel Expense (as defined below) from the Aggregate Exercise
Price as provided in Section 2(a)), the Company shall reimburse the Holder for its legal fees and expenses in connection with the preparation
and negotiation of this Agreement and transactions contemplated thereby, by paying any such amount to Schulte Roth & Zabel LLP (the
“Holder Counsel Expense”) by wire transfer of immediately available funds in accordance with the written instructions
of Schulte Roth & Zabel LLP delivered to the Company on or prior to the Closing. The Holder Counsel Expense shall be paid by the
Company whether or not the transactions contemplated by this Agreement are consummated. Except as otherwise set forth above, each party
shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such
party incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all stamp
and other taxes and duties levied in connection with the transactions contemplated hereby, if any.

 

    	15

     

    

 

(m)
Stockholder Meetings. By no later than March 11, 2022, the Company shall file with the SEC a definitive proxy statement (the “Proxy
Statement”), in the form which has been previously reviewed by the Buyers and Schulte Roth & Zabel LLP, at the expense
of the Company, for a special meeting of holders of Common Stock (the “Stockholder Meeting”), soliciting each such
stockholder’s affirmative vote at the Stockholder Meeting for approval of resolutions (“Stockholder Resolutions”)
providing for (x) the issuance of all the shares of Common Stock issuable pursuant to the December Warrants, including adjustments pursuant
to Section 2(b) of the December Warrants without giving effect to any limitation on exercise set forth therein and without giving effect
to the Exercise Floor Price (as defined in the December Warrants), (ii) resolutions approving any voluntary adjustments that the Company
may offer pursuant to the terms of any of the December Warrants and (iii) the increase in authorized number of shares of Common Stock
of the Company to at least 400,000,000 (the “Authorized Share Increase Stockholder Approval”), and the Company shall
use its reasonable best efforts to solicit its stockholders’ approval of such Stockholder Resolutions and to cause the Board of
Directors of the Company to recommend to the stockholders that they approve the Stockholder Resolutions. The Stockholder Meeting shall
be promptly called and held not later than April 10, 2022 (the “Stockholder Meeting Deadline”). No later than one
(1) Trading Day following the approval of the Stockholder Resolutions, the Company shall file with the Secretary of State of Nevada a
certificate of amendment to the Company’s Articles of Incorporation to effect the Authorized Share Increase Stockholder Approval,
which certificate of amendment shall provide that it shall become immediately effective upon filing. If, despite the Company’s
reasonable best efforts, any of the Stockholder Resolutions are not approved at the Stockholder Meeting, the Company shall cause an additional
Stockholder Meeting to be held every thirty (30) days thereafter until the approval of each Stockholder Resolution is obtained. In the
event the Principal Market has not approved the transactions contemplated by the Transaction Documents or Stockholder Approval is not
obtained on or prior to the Stockholder Meeting Deadline, the Holder (as defined in the December Warrants) may deliver one or more written
notices (each, an “Alternate Exercise Notice”) to the Company at any time during the period beginning on the Stockholder
Meeting Deadline and ending on the Expiration Date (as defined in the December Warrant) indicating that in lieu of issuing and delivering
December Warrant Shares to such holder, the Company shall promptly, but in any event within one (1) Business Day of such holder’s
delivery of such notice to the Company, pay an aggregate cash amount to such holder by wire transfer of immediately available funds pursuant
to such holder’s wiring instructions equal to such number of December Warrant Shares specified in such Alternate Exercise Notice
multiplied by $0.361 (subject to adjustments as set forth therein) to such holder in exchange for the cancellation of such number
of November Warrant Shares specified in such Alternate Exercise Notice. Notwithstanding anything in the Transaction Documents to the
contrary, these payments shall not be deemed a prepayment or trigger any other payment.

 

(n)
Amendment of September Warrants. The Company and the Holder hereby agree that:

 

a.
clause (iv) of the definition of “Excluded Securities” as defined in each Series A September Warrant is hereby and
amended and restated as follows: “; and (iv) the December Warrants (as defined in that certain Warrant Exercise Agreement, dated
as of December 20, 2021, by and between the Company and the Holder), the shares of Common Stock issuable pursuant to the terms of the
December Warrants, the November Warrants (as defined in that certain Warrant Exercise Agreement, dated as of November 11, 2021, by and
between the Company and the Holder), the shares of Common Stock issuable pursuant to the terms of the November Warrants, the September
Series B Warrants and the shares of Common Stock issuable pursuant to the terms of the September Series B Warrants; provided,
that the terms of the December Warrants, November Warrants and September Series B Warrants are not amended, modified or changed on or
after the December 20, 2021.”

 

    	16

     

    

 

b.
clause (iv) of the definition of “Excluded Securities” as defined in each Series B September Warrant is hereby and
amended and restated as follows: “; and (iv) the December Warrants (as defined in that certain Warrant Exercise Agreement, dated
as of December 20, 2021, by and between the Company and the Holder), the shares of Common Stock issuable pursuant to the terms of the
December Warrants, the November Warrants (as defined in that certain Warrant Exercise Agreement, dated as of November 11, 2021, by and
between the Company and the Holder), the shares of Common Stock issuable pursuant to the terms of the November Warrants, the September
Series A Warrants and the shares of Common Stock issuable pursuant to the terms of the September Series A Warrants; provided,
that the terms of the December Warrants, November Warrants and September Series A Warrants are not amended, modified or changed on or
after the December 20, 2021.”

 

c.
this Section 7(o) shall supersede Section 7(n) of the November WEA.

 

(o)
Amendment of November Warrants. The Company and the Holder hereby agree that the reference to “December 31, 2021”
in the definition of “Adjustment Date” in Section 19(c) of the November Warrants shall be replaced with “December 19,
2021”.

 

(p)
Amendment of November Registration Rights Agreement. The Company and the Holder hereby agree that (i) the reference to “March
1, 2022” in the definition of “Effectiveness Deadline” in Section 1(d) of the Registration Rights Agreements between
the Company and the Holder dated as of November 11, 2021 (the “November RRA”) shall be replaced with “June 15,
2022” and (ii) the reference to “January 15, 2022” in the definition of “Filing Deadline” in Section 1(e)
of the November RRA shall be replaced with “April 15, 2022”. 

 

[Signature
Page Follows]

 

    	17

     

    

 

IN
WITNESS WHEREOF, the Holder and the Company have caused their respective signature pages to this Agreement to be duly executed as
of the date first written above.

 

	 	COMPANY:
	 	 
	 	VINCO
    VENTURES, INC.
	 	 	 
	 	By:	
	 	Name:	Lisa
    King
	 	Title:
    	Chief
    Executive Officer

 

[Signature
Page to Warrant Exercise Agreement]

 

    	 

     

    

 

IN
WITNESS WHEREOF, the Holder and the Company have caused their respective signature pages to this Agreement to be duly executed as
of the date first written above.

 

	 	HOLDER:
	 	 
	 	HUDSON
    BAY MASTER FUND LTD.
	 	 	 
	 	By:	        
	 	Name:	 
	 	Title:
    	 

 

[Signature
Page to Warrant Exercise Agreement]

 

    	 

     

    

 

SCHEDULE
I

 

 

	(1)	 	(2)	 	(3)	 	(4)
	Holder
	 	Address
    and

    Facsimile Number
	 	DWAC
    Instructions
	 	Legal
    Representative’s Address and Facsimile Number

	 	 	 	 	 	 	 
	Hudson
    Bay Master Fund Ltd.	 	

	 		 	

 

    	 

     

    

 

EXHIBIT
A

 

Form
of December Warrant

 

    	 

     

    

 

EXHIBIT
B

 

Form
of Registration Rights Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}]]